Product Images Raloxifene Hydrochloride

This is a report on the percentage change in total hip bone mineral density mean from baseline in subjects taking placebo and raloxifene hydrochloride. The report includes data from two studies, NA and EU, measured every 6 months for a 24-month period. The graphs show that raloxifene hydrochloride had a higher percentage change from baseline compared to placebo in both studies. The report also includes data from a study called INT, which involve hysterectomized women taking placebo, raloxifene hydrochloride, and conjugated estrogens. The intent-to-treat analysis was used, and the last observation was carried forward.*

Each film-coated tablet contains 60 mg of Raloxifene Hydrochloride USP, manufactured by Aurobindo Pharma Limited and distributed by Northstar Rx LLC. Dosage instructions can be found in the accompanying package literature. The tablets should be stored at a controlled room temperature and should not be used if the inner seal is missing or broken. Pharmacists should dispense the medication guide to patients. This product is a product of India and has a unique product code. Some text appears to be cutoff or distorted.*